Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome
Persistent high serum triglyceride (TG) and free fatty acid (FFA) levels, which are common in metabolic syndrome and type 2 diabetes, are risk factors for cardiovascular events because of exacerbated hemorheology. To explore the effects of pemafibrate, a selective peroxisome proliferator-activated r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/4/1481 |
| _version_ | 1797620199263830016 |
|---|---|
| author | Tomohiro Iwakura Takanori Yasu Takashi Tomoe Asuka Ueno Takushi Sugiyama Naoyuki Otani Shinya Kawamoto Hiroyuki Nakajima |
| author_facet | Tomohiro Iwakura Takanori Yasu Takashi Tomoe Asuka Ueno Takushi Sugiyama Naoyuki Otani Shinya Kawamoto Hiroyuki Nakajima |
| author_sort | Tomohiro Iwakura |
| collection | DOAJ |
| description | Persistent high serum triglyceride (TG) and free fatty acid (FFA) levels, which are common in metabolic syndrome and type 2 diabetes, are risk factors for cardiovascular events because of exacerbated hemorheology. To explore the effects of pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, on hemorheology, we performed a single-center, nonrandomized, controlled study in patients with type 2 diabetes (HbA1c 6–10%) or metabolic syndrome, with fasting TG levels of ≥ 150 mg/dL and a whole blood transit time of > 45 s on a microarray channel flow analyzer (MCFAN). Patients were divided into a study group, receiving 0.2 mg/day of pemafibrate (<i>n</i> = 50) for 16 weeks, and a non-pemafibrate control group (<i>n</i> = 46). Blood samples were drawn 8 and 16 weeks after entry to the study to evaluate whole blood transit time as a hemorheological parameter, leukocyte activity by MCFAN, and serum FFA levels. No serious adverse events were observed in either of the groups. After 16 weeks, the pemafibrate group showed a 38.6% reduction in triglycerides and a 50.7% reduction in remnant lipoproteins. Pemafibrate treatment did not significantly improve whole blood rheology or leukocyte activity in patients with type 2 diabetes mellitus or metabolic syndrome complicated by hypertriglyceridemia and exacerbated hemorheology. |
| first_indexed | 2024-03-11T08:37:40Z |
| format | Article |
| id | doaj.art-6a8be702d36f4f2797208f431d8d83f7 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T08:37:40Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-6a8be702d36f4f2797208f431d8d83f72023-11-16T21:20:09ZengMDPI AGJournal of Clinical Medicine2077-03832023-02-01124148110.3390/jcm12041481Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic SyndromeTomohiro Iwakura0Takanori Yasu1Takashi Tomoe2Asuka Ueno3Takushi Sugiyama4Naoyuki Otani5Shinya Kawamoto6Hiroyuki Nakajima7Department of Cardiovascular Medicine and Nephrology, Dokkyo Medical University, Nikko Medical Center, 145-1 Moritomo, Nikko 321-2593, Tochigi, JapanDepartment of Cardiovascular Medicine and Nephrology, Dokkyo Medical University, Nikko Medical Center, 145-1 Moritomo, Nikko 321-2593, Tochigi, JapanDepartment of Cardiovascular Medicine and Nephrology, Dokkyo Medical University, Nikko Medical Center, 145-1 Moritomo, Nikko 321-2593, Tochigi, JapanDepartment of Cardiovascular Medicine and Nephrology, Dokkyo Medical University, Nikko Medical Center, 145-1 Moritomo, Nikko 321-2593, Tochigi, JapanDepartment of Cardiovascular Medicine and Nephrology, Dokkyo Medical University, Nikko Medical Center, 145-1 Moritomo, Nikko 321-2593, Tochigi, JapanDepartment of Cardiovascular Medicine and Nephrology, Dokkyo Medical University, Nikko Medical Center, 145-1 Moritomo, Nikko 321-2593, Tochigi, JapanDepartment of Cardiovascular Medicine and Nephrology, Dokkyo Medical University, Nikko Medical Center, 145-1 Moritomo, Nikko 321-2593, Tochigi, JapanDepartment of Cardiovascular Surgery, Yamanashi University, 1110 Shimokato, Chuo-shi 409-3839, Yamanashi, JapanPersistent high serum triglyceride (TG) and free fatty acid (FFA) levels, which are common in metabolic syndrome and type 2 diabetes, are risk factors for cardiovascular events because of exacerbated hemorheology. To explore the effects of pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, on hemorheology, we performed a single-center, nonrandomized, controlled study in patients with type 2 diabetes (HbA1c 6–10%) or metabolic syndrome, with fasting TG levels of ≥ 150 mg/dL and a whole blood transit time of > 45 s on a microarray channel flow analyzer (MCFAN). Patients were divided into a study group, receiving 0.2 mg/day of pemafibrate (<i>n</i> = 50) for 16 weeks, and a non-pemafibrate control group (<i>n</i> = 46). Blood samples were drawn 8 and 16 weeks after entry to the study to evaluate whole blood transit time as a hemorheological parameter, leukocyte activity by MCFAN, and serum FFA levels. No serious adverse events were observed in either of the groups. After 16 weeks, the pemafibrate group showed a 38.6% reduction in triglycerides and a 50.7% reduction in remnant lipoproteins. Pemafibrate treatment did not significantly improve whole blood rheology or leukocyte activity in patients with type 2 diabetes mellitus or metabolic syndrome complicated by hypertriglyceridemia and exacerbated hemorheology.https://www.mdpi.com/2077-0383/12/4/1481diabetes mellitusfree fatty acidmetabolic syndromemicrocirculationrheologytriglyceride |
| spellingShingle | Tomohiro Iwakura Takanori Yasu Takashi Tomoe Asuka Ueno Takushi Sugiyama Naoyuki Otani Shinya Kawamoto Hiroyuki Nakajima Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome Journal of Clinical Medicine diabetes mellitus free fatty acid metabolic syndrome microcirculation rheology triglyceride |
| title | Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome |
| title_full | Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome |
| title_fullStr | Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome |
| title_full_unstemmed | Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome |
| title_short | Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome |
| title_sort | effect of pemafibrate on hemorheology in patients with hypertriglyceridemia and aggravated blood fluidity associated with type 2 diabetes or metabolic syndrome |
| topic | diabetes mellitus free fatty acid metabolic syndrome microcirculation rheology triglyceride |
| url | https://www.mdpi.com/2077-0383/12/4/1481 |
| work_keys_str_mv | AT tomohiroiwakura effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome AT takanoriyasu effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome AT takashitomoe effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome AT asukaueno effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome AT takushisugiyama effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome AT naoyukiotani effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome AT shinyakawamoto effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome AT hiroyukinakajima effectofpemafibrateonhemorheologyinpatientswithhypertriglyceridemiaandaggravatedbloodfluidityassociatedwithtype2diabetesormetabolicsyndrome |